STL Index for: Vemurafenib

The consensus paper aims to identify the impact on patients of skin toxicities associated with cancer treatment and evidence-based best practices for skincare to minimize or prevent these changes.

There are many new immunotherapeutics that have been approved or are in clinical and pre-clinical trials to expand our arsenal in the treatment of melanoma and other previously difficult to treat malignancies.

January and February 2016: Update on drugs, approval dates, and comments. Autologous cell suspension (ReCell® ReGenerCell® ReNovaCell®), Calcipotriene 0.005% + betamethasone dipropionate 0.064% foam (Enstilar®), Ipilimumab (Yervoy®), Talimogene laherparepvec (T-Vec) oncolytic virus therapy (Imlygic™), Cobimetinib + vemurafenib (Cotellic™ + Zelboraf®), Dabrafenib + trametinib (Tafinlar® + Mekinist®), Nivolumab injection (Opdivo®) are covered.

The last couple of years have seen the beginning of a new era in the treatment of metastatic melanoma. This article focuses on BRAF inhibitors and immune modulators which have demonstrated an overall survival benefit, and the importance of limiting adverse events.

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

Update on drugs, approval dates, and comments. IncobotulinumtoxinA injection (Xeomin®), Vemurafenib tablets (Zelboraf™ cobas®), Icatibant injection (Firazyr®) are covered.